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ABSTRACT 
 
In recent years, nutrition research has moved from classical epidemiology and physiology to molecular 
biology and genetics. Following this trend, Nutrigenomics has emerged as a novel and 
multidisciplinary research field in nutritional science that aims to elucidate how diet can influence 
human health. It is already well-known that bioactive food compounds can interact with genes 
affecting transcription factors, protein expression and metabolite production. The study of these 
complex interactions requires the development of advanced analytical approaches combined with 
bioinformatics. Thus, to carry out these studies Transcriptomics, Proteomics and Metabolomics 
approaches are employed together with an adequate integration of the information that they provide. In 
this article, an overview of the current methodologies and a thorough revision of the advances in 
analytical technologies and their possibilities for future developments and applications in the field of 
Nutrigenomics is provided. 
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1. Introduction to Nutrigenomics. 
 
Diet is a key environmental factor affecting health and the incidence of many chronic diseases [1]. 
Nutrition research has traditionally explored the importance of this relation by classical approaches 
based on human intervention studies and the use of biomarkers. The effects of nutrient deficiencies, 
imbalance of macronutrients or toxic concentrations of certain food compounds on health have been 
main topics in Nutrition research [2, 3]. On the other hand, other bioactive food constituents such as 
certain polyphenols, vitamins, carotenoids and terpenoids have significant beneficial effects for health 
promotion and disease prevention by reducing the process of sustained inflammation that accompanies 
chronic disease [4, 5]. Most foods are composed of diverse constituents, many of which have specific 
biological activity. Owing to the lack of effective analytical approaches that take into account multiple 
aspects of the biological effects of food compounds, little is known about their molecular functions 
and the biological processes involved. In addition to this, bioactive food compounds also interact with 
each other, making even more difficult any effort to identify their biological activity [6].  
 
Nowadays, it is recognized that understanding the effect of diet on health requires the study of the 
mechanisms of nutrients and other bioactive food constituents at the molecular level. This is supported 
by the increasingly growing number of studies in humans, animals and cell cultures demonstrating that 
nutrients and other bioactive compounds in food can regulate gene expression in diverse ways [7]. 
More specifically, nutrients and other bioactive food constituents have been referred to as signals that 
are detected by cellular sensor systems and affect the expression of the genome at several levels 
(mRNA and proteins) and subsequently, the production of metabolites [8, 9]. These aspects have 
motivated current trends in Nutrition research to study how diet affects the balance between health and 
disease by altering the expression of an individual's genetic makeup (Nutrigenomics) or how the 
genetic variability among individuals can influence their predisposition to suffer specific illness 
related to diet as e.g., obesity (Nutrigenetics). As a consequence, Nutritional Genomics 
(Nutrigenomics and Nutrigenetics) has emerged as a new field that focuses on the study of the 
interaction between nutrition and human genome [10, 11]. The topic of this review, Nutrigenomics, 
 5 
focuses on the study of the impact of specific nutrients and diets on health through the expression of 
genetic information by the integration of “omics” technologies such as Transcriptomics, Proteomics 
and Metabolomics [12, 13].  
 
One of the main interests in Nutrigenomics research relates to health and prevention of chronic 
diseases (such as e.g., cardiovascular diseases, metabolic syndromes, cancer, etc) through diet. These 
disorders are complex and multifactorial in their origin, involving genetic factors but also a number of 
behavioural and environmental factors such as exposure to certain food components [14]. Also, it has 
been underlined the importance of the biological homeostasis maintenance for disease prevention. The 
loss of homeostasis and altered biochemical composition of cells and tissues can be primary cause in 
disease [15]. In line with this, there is a necessity for understanding the molecular mechanisms that 
describe homeostasis at biochemical, cellular and organ levels, associated with a healthy status and 
how diet affects this homeostatic control [16].  
 
As a result, there is a need for molecular biomarkers that allow early detection of the onset of disease 
or, ideally, the pre-disease state [3]. These early effect biomarkers should accurately reflect subtle 
changes in homeostasis and the efforts of the body to maintain it [16]. However, the discovery of such 
biomarkers is not easy since diet-gene interactions are complex. Unlike the comparative simplicity of 
the single-gene disorders, chronic diseases are likely the result of multiple genes and multiple variants 
of each gene interacting with multiple environmental factors, each combination making a relatively 
small contribution to overall homeostasis, function and health. Thus, to determine health status and 
reflecting the functional response to a bioactive food component [8], complete biomarker profiles of 
gene expression, protein expression and metabolite production will be more useful than single 
markers. To do this, the availability of advanced analytical techniques will be essential for the 
investigation of complete biomarker profiles of gene expression, protein expression and metabolite 
production. 
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The mentioned profiles can be considered as 'dietary signatures' that Nutrigenomics will use to 
understand the cellular functions of nutrients and other active food components and how they affect 
homeostasis in specific tissues within the whole organism. To attain this, Nutrigenomics makes use of 
an integrated analytical approach including the latest developments in high-throughput –omics 
techniques for the comprehensive study of different aspects of this biological complexity. This 
integrated analytical approach puts together Transcriptomics, Proteomics and Metabolomics, and 
might also be ideal for elucidating the effects of novel functional foods and nutraceuticals on global 
expression of genetic information and cell function without making assumptions about what to look 
for in terms of risk, and providing new means for discovering biomarkers for efficacy testing of 
bioactive functional food ingredients [1]. 
 
The development of Genomics, Transcriptomics, Proteomics and Metabolomics [17] has created 
extraordinary opportunities for increasing our understanding about (i) the biochemical, molecular and 
cellular mechanisms that underlies the beneficial or adverse effects of certain bioactive food 
components; (ii) the identity of genes that are involved in the previous stage to the onset of the 
disease, and therefore, possible molecular biomarkers; and (iii); the effect of bioactive food 
constituents on crucial molecular pathways [8, 18]. In the following sections, the main characteristics 
of these –omics techniques and their use in Nutrigenomics are reviewed. 
 
2. Advances in Transcriptomics. 
 
In the expression process of genomic information, several steps may be regulated by nutrients and 
other bioactive compounds in food. Consequently, the analysis of changes in mRNA expression by 
nutrients and bioactive food constituents is often the first step to study the flow of molecular 
information from the genome to the proteome and metabolome and one of the main goals in 
Nutrigenomics research [8]. For years, the expression of individual genes has been determined by 
quantification of mRNA with Northern blotting. This classical technique has gradually been replaced 
by more sensitive techniques such as real-time PCR. Both techniques, however, can only analyse gene 
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expression for a limited number of candidate genes at a time. This is an important limitation for their 
application in Nutrigenomics research since the analysis of a reduced number of genes may not 
provide insights about the causative relationship between the bioactive food constituent and its 
biological effect [19].  
 
On the opposite, the analysis of global gene expression may offer better opportunities to identify the 
effect of bioactive food constituents on metabolic pathways and homeostatic control and how this 
regulation is potentially altered in the development of certain chronic diseases [13]. In the past decade, 
two conceptually different analytical approaches have emerged to allow quantitative and 
comprehensive analysis of changes in mRNA expression levels of hundreds or thousands of genes. 
One approach is based on microarray technology, and the other group of techniques is based on DNA 
sequencing [20].  
 
2.1 Gene expression microarray technology. 
 
During the last years, owing to the extensive optimization and standardization, gene expression 
microarray has become a leading analytical technology in Nutrigenomics research for the investigation 
of the interactions between nutrients and other bioactive food compounds and genes [15, 19, 21]. 
 
Typically, DNA microarrays are collections of oligonucleotides or probes, representing thousands of 
genes, attached to a substrate, usually a glass slide, at predefined locations within a grid pattern. This 
technique is based on specific nucleic acids hybridization and it can be used to measure the relative 
quantities of specific mRNAs in two or more samples for thousands of genes simultaneously.  
 
Regardless the platform used for the analysis, the typical experimental procedure is based on the same 
analytical steps: RNA is extracted from a source of interest (tissue, cells, or other materials), labelled 
with a detectable marker (typically, fluorescent dye) and allowed to hybridize to the microarrays with 
individual DNA sequences hybridizing to their complementary gene-specific probes on the 
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microarray. Once hybridization is complete, samples are washed and imaged using a confocal laser 
scanner (Figure 1). Theoretically, the fluorescent signal of derivatized-nucleic acids bound to any 
probe is a function of their concentration. The relative fluorescence intensity for each gene is extracted 
and transformed to a numeric value [22].  
 
Gene expression microarrays are powerful, but variability arising throughout the measurement process 
can obscure the biological signals of interest. In order to fully exploit the possibilities of DNA 
microarrays, a careful study of the experimental design is required [23]. Data acquisition and pre-
procesing are important post-technical steps in microarray experiments. The latter involves data 
normalization, which consists of adjusting the individual hybridization intensities in order to remove 
variation derived from unequal quantities of starting RNA, differences in labelling or detection 
efficiencies between the fluorescent dyes used, and systematic biases in the measured expression 
levels. The most common approaches adopted for normalization are total intensity normalization, 
Locally Weighted Scatterplot Smoothing (LOWESS) and the use of housekeeping genes [24, 25]. 
 
Differences in precision, sensitivity, or specificity between different microarray platforms, makes 
comparisons between experimental platforms unreliable. Moreover, the annotations across different 
platforms are not represented by exactly the same gene sequence regions. In order to alleviate in part 
cross-comparison problems among distinct microarray platforms, the Microarray Gene Expression 
Data (MGED) organization [26] has established Minimum Information About a Microarray 
Experiment (MIAME) guidelines for microarray data annotation and reporting. These guidelines, 
aimed to improve the data sharing between platforms, have been adopted by a number of scientific 
journals. Furthermore, in an effort to make MIAME-compliant data publicly available, the 
ArrayExpress microarray database [27] has been created as a repository for Transcriptomics 
experimental data. In addition, this database accepts processed data files generated with the very 
recent RNA-Seq technologies that will be discussed later. Also, ArrayExpress Atlas [28] is a recent 
tool developed to allow the user to query for conditions-specific gene expression across multiple data 
sets within the increasingly growing ArrayExpress database [29]. 
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The analysis of the vast amount of microarray data for extracting biologically meaningful information 
is perhaps the most challenging and daunting tasks [30]. The fundamental goal of microarray 
expression profiling is to identify genes that are differentially expressed in the condition of interest 
[31]. Data analysis process can be divided into three main parts: Identification of significantly 
regulated genes, identification of global patterns of gene expression, and determination of the 
biological meaning of both individual genes and group genes. First, filtering criteria, including fold 
change and statistical significance determined by comparison statistics is necessary in order to identify 
candidate genes that are differentially expressed. After filtering data, the differentially expressed genes 
are then classified into discrete groups or clusters, based on expression pattern. This step allows the 
identification of groups of co-regulated genes. To achieve this, sophisticated bioinformatics tools such 
as unsupervised clustering, principal component analysis and self-organizing maps are the most 
widely used [32, 33].  
 
Most of microarray studies published to date corroborate the gene expression data by an alternative 
sensitive technique. In general, there is a good correlation between microarray results and other more 
traditional methods, indicating the ability of the technology to produce reliable results [33]. The 
validation is generally performed by analysing a selection of differentially expressed genes of interest 
in the samples using real-time, quantitative reverse transcriptase polymerase chain reaction (RT-PCR) 
[35-38], although other methods such as Northern blotting [39], quantitative radioactive in situ 
hybridization and verification at the level of the protein, through routine western blotting [40], 
immunohistochemical or immunocytochemical assays has been also used [31, 41]. In RT-PCR 
analysis, mRNA is converted into cDNA and subsequently amplified in a PCR by specific primers in 
the presence of a fluorescent dye or internal probes. The expression level of the target gene is 
computed relative to the expression level of one or more reference genes, often housekeeping genes. 
Selecting proper housekeeping genes is one of the most critical aspects of the analysis, since they need 
to be constantly expressed between all samples and conditions in the experiment. In a recent study, the 
application of a 96-well plate PCR-array analysis for validation of microarray data suggested that most 
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differences between the results obtained by two different technologies were attributed to saturation 
problems in the microarray, strict quality criteria for array-PCR data analysis, and possible differences 
in isoforms detected by the two technologies [21].   
 
Early applications of microarray to Nutrigenomics were related to the effects of caloric restriction on 
aging [42-45]. Soon, the technology was extended to study other interesting aspects in Nutrigenomics 
including the effects of dietary protein in the gene expression of cells [46, 47], the mechanisms dietary 
long chain polyunsaturated fatty acids in molecular function cancer and normal cells [48, 49] and the 
effects on transcriptome of a high- or low-carbohydrate intake [50, 51]. The molecular mechanisms of 
certain bioactive food constituents have also been investigated by microarray technology. A summary 
of some representative applications of microarray in Nutrigenomics field is given in Table 1.  
 
2.2. Sequencing-based technologies. 
 
In contrast to microarray technology, sequencing-based techniques consist of counting tags of DNA 
fragments to provide “digital” representation of gene expression levels using sequencing. These 
techniques include Serial Analysis of Gene Expression (SAGE) [57] and some of its variants, 
including LongSAGE [58], Cap Analysis of Gene Expression (CAGE) [59], Gene Identification 
Signature (GIS) [60]. In SAGE-based methods, the abundance of a particular mRNA species is 
estimated from the count of tags derived from one of its ends. First, restriction enzymes are used to 
obtain short tags of 14-21 bp, usually derived from one end of an mRNA, which are then 
concatenated, cloned and sequenced to determine the expression profiles of their corresponding 
mRNAs. Despite the more statistical robustness and less stringent standardization and replication 
requirements than those used for microarrays, the size of the sample tags should be increased in order 
to improve the precision and accuracy for detecting rare mRNAs [61]. Unfortunately, most of these 
methods are based on expensive Sanger sequencing method and, therefore, sequenced SAGE library 
rarely exhibits saturating tag counts that would indicate complete representation of the cellular 
transcriptome [62]. An additional limitation of these techniques is that owing to short length, many 
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SAGE tags are shared by the transcripts from different genes, which can complicate gene 
identification [63]. Moreover, the many PCR amplifications, cloning and bacterial cell propagations 
that these techniques involve may result in a quantitative bias for different tags [64]. Massively 
Parallel Signature Sequencing (MPSS) is a more sophisticated “clone-and-count” technique that also 
generates small tags of each mRNA species; however, it uses a different strategy that does not involve 
propagation in bacteria neither Sanger sequencing [62]. Nevertheless, the MPSS technology has been 
restricted to only a few specialized laboratories [64]. 
 
In the past few years, the development of “next-generation” sequencing methods, also referred to as 
either “massive parallel” or “ultra-deep” sequencing, is changing the way in which gene expression is 
studied [20, 65]. These novel technologies have had an enormous impact on research in a short time 
period, and it is likely to increase further in the future. Although they have not been applied in 
Nutrigenomics yet, their potential is underlined by their adoption in studies of transcriptomes during 
physiological changes, and for the comparative analysis between different disease states or conditions 
[66].  
 
Next-generation sequencing technologies apply distinct concepts and procedures aimed to increase 
sequencing throughput in a cost-effective and rapid manner. Last advances in emulsion PCR and non-
cloning based methods for DNA amplification, together with improved imaging instruments have 
facilitated the development of sequencers capable of reading up to tens of million of bases per run in a 
massively parallel fashion [67-69]. The read lengths typically achievable by these technology range 
from 30 to 300 bp, depending on the sequencing platform used. These short reads will represent a 
challenge for either mapping them to reference genome or de novo assembling without genomic 
reference [69].  
 
The new features of next-generation sequencers have stimulated the development of new techniques 
that have expanded their applications, for example, to comprehensively map and quantify 
transcriptomes, which with Sanger sequencing would not have been economically or logistically 
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practical before [70, 71]. Similarly to the concept adopted in SAGE and MPSS, the principle behind 
these novel techniques for Transcriptomics, which have been termed RNA-Seq methods, is based on a 
global sequence census approach. Generally, a complex RNA sample is converted to a library of 
cDNA with adaptors attached to one or both ends. cDNA molecules, with or without amplification 
(depending on the sequencing platform), are subjected to massively parallel sequencing in short reads 
without bacterial cloning as a pre-requisite. Following sequencing, powerful bioinformatics tools are 
needed in order to align the resulting short reads (30-300 bp), depending on the sequencing platform 
and method used, to a reference genome or reference transcripts. That is, with reference genomes 
available, short reads are sufficient to map their locations rather than sequencing the entire large 
genome. Once mapped, the sequence hits are counted to determine their density and distribution and 
then, quantify the gene expression [72]. RNA-Seq is still a technology under active development that 
is being evaluated in multiple laboratories for RNA profiling [73-77] and other applications such as 
discovery of small RNAs, mapping RNA splice isoforms and discovery of small RNAs [78-80]. 
 
2.3. Bioinformatics and Gene Ontology database. 
 
As mentioned, high-throughput technologies in transcriptomics usually generate large lists of 
differentially expressed genes as final output. However, the biological interpretation of such results is 
very challenging. Over the last years, the use of biological knowledge accumulated in public databases 
by means of bioinformatics, allows to systematically analyse large gene lists in an attempt to assemble 
a summary of the most enriched and significant biological aspects [81]. The principle behind 
enrichment analysis is that if a certain biological process is occurring in a given study, the co-
functioning genes involved should have a higher (enriched) potential to be selected as a relevant group 
by high-throughput screening technologies. This approach increases the probability for researchers to 
identify the correct biological processes most pertinent to the biological mechanism under study [82]. 
Thus, a variety of high-throughput enrichment tools (e.g. DAVID, Onto-Express, FatiGO, GOminer, 
EASE, ProfCom, etc.) have been developed since 2002 in order to assist microarray end user to 
understand the biological mechanisms behind the large set of regulated genes. These bioinformatics 
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resources systematically map the list of interesting (differentially expressed) genes to the associated 
biological annotation terms and then statistically examine the enrichment of gene members for each of 
the terms by comparing them to a control (or reference). A recent work by Leong et al. shows the 
potential of exploiting bioinformatics tools for extracting valuable biological information from 
microarray experiments. In their work, the use of Affymetrix microarray platform and stringent data 
analysis provided interesting insights into a homeostatic mechanism, based on arginine-sensitive 
regulation that coordinates aspects related to nutrient availability in hepatic cells [38]. 
 
Enrichment analysis would not be possible without appropriately structured databases such as Gene 
Ontology [83]. More specifically, Gene Ontology provide a systematic and controlled language, or 
ontology, for the consistent description of attributes of genes and gene products, in three key 
biological domains that are shared by all organisms: molecular function, biological process and 
cellular component. Thus, standard biological phrases, referred to as terms, which are applied to genes 
and proteins are then, linked or associated with other Gene Ontology terms by trained curators at 
genome databases [84]. A recent study of the effects of soy isoflavones, based on gene expression 
microarray data, has revealed potential mechanisms of action for genistein by the combined use of 
GoMiner as the enrichment tool, Gene Ontology database and information from Dragon Estrogen 
Responsive Genes Database [24]. In addition to the aforementioned Gene Ontology database, recent 
enrichment tools also integrate information extracted from other databases as for instance, the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathways (metabolites) in order to improve the 
comprehensiveness of this type of studies [82]. 
 
3. Advances in Proteomics. 
 
The proteome is the set of expressed proteins at a given time under defined conditions, it is dynamic 
and varies according to the cell type and functional state. In the case of a Nutrigenomic study, the 
proteome provides a “picture” of the impact of specific bioactive nutrients and diets in a certain 
organism, tissue or cell in a particular moment. Thus, the importance of Proteomics as a tool to 
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understand the effect of the diet on health has already been recognised by several authors [18, 85-90], 
however, up to now the application of Proteomics in Nutrigenomics is still rather limited, being the 
number of review papers higher than research papers [91]. 
 
One of the main differences when working with proteins is that there is not an amplification 
methodology for proteins comparable to PCR. Physical and chemical diversity of proteins are also 
higher than nucleic acids. They differ among individuals, cell types, and within the same cell 
depending on cell activity and state. In addition, there are hundreds of different types of post-
translational modifications (PTMs), which evidently will influence chemical properties and functions 
of proteins. PTMs are key to the control and modulation of many processes inside the cell. The 
selected analytical strategy for the detection of PTMs will depend on the type of modification: 
acetylation, phosphorylation, ubiquitination, sumoylation, glycosylation, etc. It is already known that 
dietary components can also modify the translation of RNA to proteins and the post-translational 
procedures [92]. Thus, it has been observed that dietary components such as diallyl disulfide, 
acompound found in processed garlic, has been shown to post-translationally modify proteins [92]. In 
other cases post-translational regulation of proteins by dietary components can involve the 
modification of their thiol groups [93]. 
 
Another important drawback in the proteome study is the huge dynamic concentration range of 
proteins in biological fluids or tissues. Namely, a 10
10
 dynamic range has been estimated in serum for 
protein concentration [94]. This situation causes many detection difficulties due to a large number of 
proteins are below the level of sensitivity of the most advanced instruments. For this reason, in 
Proteomics fractionation and subsequent concentration of the proteome is often needed [95, 96]. In a 
first instance, in order to reduce the complexity of the sample, fractionation of the proteome can be 
done by differential centrifugation into different populations of organelles [97] and also attending 
solubility properties into different cellular compartments. The chemical tagging strategies, involving 
the modification of functional groups of amino acid residues, including PTM in proteins (and 
peptides) is the methodology of choice when a specific population of the proteome is under study [98]. 
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Another strategy for proteome fractionation that is gaining more and more significance is the 
sequential or simultaneous immuno-affinity depletion of the most-abundant proteins [99]. It has 
become the alternative in certain application, however, the main drawback regarding this approach is 
that co-depletion of a certain fraction of the proteome with the abundant proteins can occur. 
Chromatographic [100] and electrophoretic [101] strategies have also been applied to the pre-
fractionation of the proteome. In general, the main problem of the mentioned strategies is that after 
fractionation or depletion, the remaining proteins (in case of depletion) or the proteins in the fractions 
of interest remain dilute, being still in not enough concentration for subsequent analysis. Most 
recently, it has been described the use of a library of combinatorial ligands, acting by reducing the 
signal of high-abundance proteins while increasing the level of the low-abundance ones to bring their 
signal within the detection limit of the present-day analytical instruments [102]. 
 
Because of the complexity of proteome the use and development of high-resolving separation 
techniques as well as highly accurate mass spectrometers is nowadays critical in Proteomics [103, 
104]. Currently, more than a single electrophoretic or chromatographic step is used to separate the 
thousands of proteins found in a biological sample. This separation step is followed by analysis of the 
isolated proteins (or peptides) by mass spectrometry (MS) via the so-called “soft ionization” 
techniques, such as electrospray ionization (ESI) and matrix-assisted laser desorption/ionization 
(MALDI), combined with the everyday more powerful, easy to use and affordable mass spectrometers. 
 
Although Proteomics has been scarcely applied to study the effect of nutrients on health, two 
fundamental analytical strategies can be employed: the bottom-up and the top-down approach. Both 
methodologies differ on the separation requirements and the type of MS instrumentation. 
 
3.1 Bottom-up approach. 
 
The bottom-up approach is the most widely used in Proteomics since it can apply conventional or 
modern methodologies. In a conventional approach, large-scale analyses of proteomes is accomplished 
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by the combination of two-dimensional gel electrophoresis (2DE) followed by MS analysis [105]. 
2DE is the methodology that currently provides the highest protein species resolution capacity with 
low-instrumentation cost. However, 2DE is laborious, time-consuming and presents low sensitivity, 
depending strongly on staining and visualization techniques. 2DE has also some limitations to separate 
highly hydrophobic biomolecules or proteins with extreme isoelectric point or molecular weight 
values. Moreover, one of the major sources of error in 2DE is gel-to-gel variation. In this sense, the 
introduction of difference gel electrophoresis (DIGE), in which gel variation is eliminated by loading 
different samples in the same gel [106], has brought about an important improvement. DIGE 
methodology is based on the use of novel ultra high sensitive fluorescent dyes (typically, Cy3, Cy5 
and Cy2) to label up to three different protein samples that will be separated in the same 2DE run. 
After image analysis of the 2DE gels, the protein spots of interest are subsequently submitted to an in-
gel digestion step with a protease enzyme. MS and databases of protein sequences are then use in 
different ways for protein identification, following: (i) the peptide mass fingerprint (PMF) approach 
using MS data, in which the molecular masses of the peptides from the protein digest are compared 
with those simulated of already sequenced proteins, or (ii) by tandem MS in a sequence tag search in 
which a few peptidic sequences obtained from MS/MS analysis (using collisional activation or some 
other energy deposition process) can be used to search in protein databases. The main limitation of the 
bottom-up approach is that information obtained is related to a fraction of the protein, loosing 
information about PTM. 
 
There are limited studies on the effect of specific natural compounds, nutrients or diets on the 
proteome, being most of them based in the bottom-up approach, more precisely in classical 2DE-MS, 
although also LC-MS/MS has been applied with this purpose. These studies are summarized in Table 
2.  
 
Shotgun Proteomics is an advanced bottom-up approach in which a complex protein mixture is 
digested with endoproteinases of known specifity [119], providing a comprehensive, rapid and 
automatic identification of complex protein mixtures. In spite of the higher sample complexity due to 
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the huge number of peptidic species obtained from the protein mixture hydrolysate, peptides are in 
general better separated and analyzed by MS than proteins.  
 
An essential part of shotgun Proteomics is the use of powerful and highly resolving separation 
methods prior to MS analysis, allowing the study of complicated biological samples while avoiding 
suppression ionization problems. Liquid chromatography (LC) [120] and capillary electrophoresis 
(CE) [121, 122] in their different modes are the main methodologies applicable to the separation of 
complex peptide mixtures due to their high resolving power and their potential for full automation and 
high sampling rates. Although physico-chemical diversity of peptides makes them well suited to be 
separated by different liquid-based separation modes, reversed phase (RP) and aqueous mobile phases 
are normally used for the chromatography of peptides. Special attention has been put in 
miniaturization of columns through the reduction of column diameters and sorbent particles, as in the 
case of ultra performance LC systems (an LC system using sub-2 μm packing columns combined with 
high operating pressures), as well as the use of instruments capable of delivering nanoliter/min flow 
rates such us nano-scale liquid chromatography (nLC). On the other hand, CE combined with MS has 
also come out as an effective strategy for proteomic studies, since CE is a robust system that provides 
fast and high resolution separations employing inexpensive capillaries [123]. Special attention is 
currently being paid to the use of CE in microchips since it provides much shorter separation times 
[124], lower sample and reagent consumption than nLC and CE. Due to the analytical characteristics 
of these micro-devices further high-throughput in shotgun Proteomics is expected in the near future. 
 
To carry out shotgun Proteomics most efforts have been focused on the development of on-line 
combination of various chromatography and/or electrokinetic separation methods, as well as in 
multidimensional protein identification technology (MudPIT), coupled with MS or tandem MS [125, 
126] (Figure 2). The vast majority is based on the combination of ion exchange chromatography and 
reversed-phase (RP) chromatography. It has also been described the great potential of monolithic 
compared to particle-based columns due to monolithic can be used together with higher flows and 
gradients [127]. This is of special interest in a multidimensional chromatography setup where the 
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separation and identification of a vast number of analytes in a short time is mandatory mainly in the 
second dimension. Other novel couplings have been described, as for instance those based on 
hydrophilic interaction liquid chromatography (HILIC) [128]. The capabilities of multidimensional 
systems involving on-line combination of capillary isoelectric focusing (CIEF) with nano-RPLC have 
also been demonstrated to be effective in the analysis of proteins and peptides [129] creating new and 
encouraging perspectives in the discovery of biomarkers in Nutrigenomics studies. 
 
ESI has been the interface of choice to ionize peptides eluted from LC or CE columns and to analyze 
them by MS: from the lower resolving power ion trap instruments able to generate MS
n
 spectra, to the 
more advanced hybrid instrumentation such us quadrupole-time of flight (Q-TOF), TOF-TOF and the 
recently introduced hybrid linear ion trap (LTQ)-Orbitrap (Orbitrap
TM
) [130]. Some proteomic studies 
have also focused on the use of MALDI interface for chromatographic separations and MS. The 
technical problems generated by the non-atomospheric working conditions required by MALDI 
interface could be compensated for a lower interference with sample matrix and chromatographic 
eluents and an improvement on proteome coverage [131].  
 
3.2 Top-down approach. 
 
A growing number of researchers are focusing on the use of top-down Proteomics, a relatively new 
approach compared to bottom-up, in which structure of proteins is studied through measurement of 
their intact mass followed by direct ion dissociation in the gas phase [132]. The main advantages over 
the bottom-up approach are that higher sequence coverage is obtained, it permits the study of PTM and 
it makes possible to discern between biomolecules with a high degree of sequence identity.  
 
Today, Fourier transform ion cyclotron resonance (FTICR) MS offers the highest mass resolution, 
resolving power, accuracy and sensitivity among present MS technologies [133]. Nevertheless, its 
high purchase, and maintenance costs, mostly derived from the expensive superconducting magnet and 
liquid helium supply required, precludes its general use.  Thus, a variety of instruments have been 
 19 
used for top-down Proteomics, such us MALDI-TOF/TOF, ESI-Q/TOF, ESI-IT and the novel 
Orbitrap
TM
, suitable for routine top-down Proteomics as recently reported [134]. In those cases in 
which the molecular mass of proteins exceeds the analytical power of the mass spectrometer, they can 
be subjected to a limited proteolysis to produce large polypeptides that are then analyzed employing 
top-down Proteomic approaches. This has been called the middle-down approach, maintaining the 
advantages of high sequence coverage and PTM information. 
 
A key to the top-down approach is the capacity to fragment intact proteins inside the mass 
spectrometer. Usually, low-energy multiple collision-induced dissociation (CID) is used, although 
ultraviolet photodissociation (UVPD) [135], infrared multiphoton dissociation (IRMPD) [136], and 
blackbody infrared radiative dissociation (BIRD) [137] can be found in literature. Alternative 
dissociation techniques such us electron capture dissociation (ECDβ) represents one of the most recent 
and significant advances in tandem MS [138]. This alternative technique is based on the fragmentation 
of multiple charged protein cations due to interaction with low-energy electrons. A newer dissociation 
method similar to ECD is electron transfer dissociation (ETD), which also uses charge reduction by 
electron transfer [139]. Both charge reduction dissociation techniques, ECD and ETD initially used in 
FTICR-MS and now extended to (LTQ)-Orbitrap instruments provide more extensive sequence 
fragments over the entire protein backbone preserving the PTM after cleavage, resulting in easier 
identification of the modification sites. 
 
Top-down Proteomics approaches are usually limited to simple protein mixtures since very complex 
spectra are usually generated by multiple charged proteins. In general, a protein isolate from a 
previous fractionation or purification step is directly infused to the high-resolution MS. In this regard, 
due to the capabilities of CE for complex protein separation, CE coupling with high-resolution MS is 
one of the most promising methodology in top-down studies [140]. However, improved ECD and ETC 
speed will be needed for future high-throughput CE-MS (and also LC-MS) applications in top-down 
Proteomics. 
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3.3. Other proteomic approaches 
 
New Proteomic approaches are under development, with a growing increase of works focused on the 
detection of protein biomarkers. One of the approaches that is gaining popularity is based on the array 
technology. Protein microarrays can be composed by recombinant protein molecules or antibodies 
immobilized in a high-density format on the surface of a substrate material. There are two major classes of 
protein micro- (or nano-) arrays: analytical and functional protein microarrays, being the antibody-based 
microarray the most common platform in proteomic studies [141]. This miniaturized arrays can be 
fabricated with an almost infinite number of antibodies (in the particular case of antibody microarrays) 
carrying the desired specificities and being capable of simultaneously profiling numerous low-abundant 
protein analytes in complex proteomes, while consuming only a few microliters of sample. The microarray 
patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, 
revealing the composition of the proteome. After import data files from the microarray scanning 
sources and normalization and quantification of protein microarrays, a statistical analysis has to be 
carried out.  
 
Surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF MS), an 
emerging tool for protein profiling and biomarker discovery applicable to minute amounts of starting 
material [142] can also be used as a complementary, rapid and high-throughput proteomic approach to 
identify differentially expressed peptides and proteins and, therefore, can help to save time and 
research effort in studies about the effect of bioactive food components on the proteome. This 
technology enables to speed up the process significantly with the capacity to run and analyze several 
hundreds samples in parallel per day. Different SELDI chip types have different surfaces, depending 
on the type of proteins to be analyzed, range from chromatographic chemistries, to surfaces with a 
specific biomolecular affinity (e.g. antibodies, receptors, enzymes and ligands) that bind one specific 
protein or group of proteins. The efficacy of the SELDI-TOF technology has been proved in the 
analysis of plasma samples (previously fractionated by anion-exchange chromatography) by quickly 
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identifying the proteins whose expression changed in response to vitamin A status from retinol-
sufficient and retinol-deficient rats [143] (Figure 3). 
 
4. Advances in Metabolomics. 
 
As defined by Trujillo et al [144], the metabolome can be described as the full set of endogenous or 
exogenous low molecular weight metabolic entities of approximately < 1000 Da (metabolites), and the 
small pathway motifs that are present in a biological system (cell, tissue, organ, organism or species). 
The most common metabolites are amino acids, lipids, vitamins, small peptides or carbohydrates. 
Metabolites are the real endpoints of gene expression and of any physiological regulatory processes. 
Therefore, according to some authors [12], any change in metabolite concentration may describe better 
the biochemical state of a biological system than proteomic or transcriptomic variations.  
 
The objective of Metabolomics within the frame of Nutrigenomics is to investigate the metabolic 
alterations produced by the effect of nutrients or bioactive food constituents in the different metabolic 
pathways. Its importance not only lays on the information obtained about the molecular events 
involved in nutrition and how the body adapts through metabolic pathways to different nutrient fluxes, 
but also on the identification of certain  metabolites such as cholesterol or glucose as biomarkers for 
health or disease status [145].  
 
There are three basic approaches used in Metabolomic research; target analysis, metabolic profiling 
and metabolic fingerprinting. Target analysis aims the quantitative measurement of selected analytes, 
such as a specific biomarker or reaction product. Metabolic profiling is a non targeted strategy that 
focuses on the study of a group of related metabolites or a specific metabolic pathway. It is one of the 
basic approaches to phenotyping as the study of metabolic profiles of a cell gives a more accurate 
description of a phenotype [146]. Meanwhile, metabolic fingerprinting does not aim to identify all 
metabolites, but to compare patterns of metabolites that change in response to the cellular environment 
[147].  
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Metabolomics has diverse applications such as biomarker discovery, determination of the metabolic 
effects of environmental changes in the body or early disease detection [148]. The most relevant 
application of Metabolomics in Nutrigenomics is the possible health benefits provided by the ingest of 
functional compounds. In this regard, the effects of phytochemicals in human health are the most 
studied. Some examples are the potential benefits of flavones in heart diseases, of stannols in 
cholesterol metabolism, and soy-based estrogen analogues in cancer [149]. Because of the extensive 
consumption of polyphenols in the diet, and its association with health benefits, the biological activity 
of these compounds is an important topic of investigation in Nutrigenomics [150].  
 
Application of Metabolomics in Nutrigenomics (or Nutritional Metabolomics) is, however, even more 
complex than in other areas of research. Humans feed on other organisms, each with its own 
metabolome, so the number of different metabolomes that conform our diet is significant enough to 
make Nutrigenomics a very complex discipline [151]. Therefore, there are several challenges that 
Metabolomics has to face in human nutrition. In general, metabolism is dynamic and depends on the 
different cellular environments and physiological situation, so it is hard to understand the effects 
separately and to link directly metabolites to genes and proteins [152]. In Nutritional Metabolomics 
the complex interactions between gut microflora and host metabolism as well as other extrinsic factors 
such as food habits, diet and other lifestyle parameters give rise to high metabolic variability [153-
156].  
 
One of the advantages of Nutritional Metabolomics is that there are several accessible body fluids that 
contain possible biomarkers in human body. To date, most Metabolomics studies in mammals have 
used urine as the vehicle for investigation and, in the field of Nutrigenomics blood and urine are the 
most likely candidates for sample choice [157].  
 
4.1. Analytical techniques in Metabolomics. 
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Unlike Transcriptomics or Proteomics, which intend to determine a single chemical class of 
compounds (mRNA or proteins), Metabolomics has to deal with very different compounds of very 
diverse chemical and physical properties. Moreover, the relative concentration of metabolites in the 
biofluids vary from millimolar level (or higher) to picomolar, making it easy to exceed the linear range 
of the analytical technique employed. As no single technique can be expected to meet all these 
requirements, many Metabolomics approaches can employ several analytical techniques [12, 151]. 
 
Metabolomics is an emerging technology, so new analytical techniques and methods are continuously 
being developed and will continue in the near future in order to achieve its goals. So far, 
Metabolomics is proving to be very useful for the analysis of metabolic patterns and changes in the 
metabolism derived from different situations in the cellular environment. This is certainly interesting 
in the nutrition field as can determine variations in different metabolic pathways due to the 
consumption of different compounds in the diet.  
 
In order to gain a detailed knowledge on human metabolism by means of Metabolomic tools, the ideal 
steps should be first to elucidate the nature and concentration of the searched metabolites and second 
to share the information in accessible databases [88] (Figure 4). The two most common analytical 
techniques used so far in Metabolomics are nuclear magnetic resonance (NMR) and MS. Thus, as a 
general result it can be stated that the influence of diet in metabolism has been clearly established 
using these techniques. For example, the effect of diet on urea cycle and purine metabolic pathways 
was demonstrated using both 
1
H-NMR and ion trap MS [158]. Another study involving the use of both 
1
H-NMR spectroscopy and high performance liquid chromatography (HPLC) coupled to a Q-TOF MS 
reported that acute changes in human urinary metabolomic profiles occur after the consumption of 
dietary phytochemicals [159].  
 
4.1.1 Mass spectrometry (MS) approaches. 
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MS can be used as a stand alone technique or most commonly combined with a preliminary 
chromatographic separation technique, either gas chromatography (GC), high performance 
chromatography (HPLC) with MS (HPLC-MS) or CE-MS [151]. Direct injection is performed for 
Metabolomics with high or ultra high resolution mass analyzers as TOF-MS (mass accuracy < 10 
ppm) or FTICR-MS which provides a mass accuracy < 1 ppm and detection limits lower than attomole 
or femtomole levels. These characteristics make them ideal tools for metabolomic studies as was 
shown by Rosello-Mora et al [160] which stated that different strains of Salinibacter ruber could be 
differentiated by some characteristic metabolites. Hybrid analyzers, as for example Q-TOF, have the 
advantages of mass accuracy given by a TOF analyzer combined with the possibility to fragment the 
ions and thus, provide information about the structure of the detected metabolites [161]. These kind of 
analyzers should lead the metabolomic studies in the near future. As for Proteomics, the most usual 
ionization techniques are the ones that use atmospheric pressure ionization, especially ESI interfaces, 
as it can work with a wide range of polarities [162].  
 
Mass accuracy and resolution provided by MS instruments are usually not enough to undoubtedly 
separate and identify all metabolites in a sample by direct infusion. A complete methodology for 
metabolite elucidation is provided by Chen et al. [163] in the metabolomic identification of 
biomarkers of individuals at risk of diabetes. To overcome these limitations MS analyzers are usually 
coupled to separation techniques for metabolomic studies. Thus, GC-MS are so far the most common 
couplings for metabolomic studies. A GC-MS method for the analysis of flavonoids, a sub class of 
polyphenols, in urine and plasma has been developed [164]. In this method, liquid-liquid extraction, 
derivatization and analysis by GC-TOF-MS have been optimized, providing limits of detection below 
0.1 μg/ml for most phenolic acids. This method identified 11 phenolic acids in urine samples whose 
concentration increased after tea consumption.  
 
Apart of GC, other separation techniques have also been successfully coupled to MS instruments to 
carry out Nutritional Metabolomics. Thus, Yin et al. [165] have recently developed a reliable 
metabolic profiling method for human serum analysis using a C-18 column coupled to a Q-TOF-MS 
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analyzer. The aim of this LC-Q-TOF-MS strategy was to identify potential biomarkers and the 
metabolic pathways altered by an herbal preparation used to treat some diseases such as cardiovascular 
problems or cancer.  
 
The most recent introduction into the field of separation techniques with enormous potential in 
Metabolomics research is the ultra performance liquid chromatography coupled to MS (UPLC
TM
-MS) 
technology. UPLC
TM
-MS has been used in the determination of metabolic profiles in human urine 
[166]. The small particle size and the high pressure allow to reduce analysis time approximately ten 
times respect to conventional LC while increasing efficiency and maintaining resolution.  
 
4.1.2 Nuclear magnetic resonance (NMR) approaches. 
 
NMR is a high reproducibility technique that has demonstrated its great potential in Metabolomics 
studies [167]. Using this analytical technique, Wang et al. have studied the relationship between the 
consumption of chamomile tea and some human biological responses. Statistical differences in three 
different excreted metabolites between high-resolution 
1
H-NMR analyses of urine samples taken 
before and after chamomile tea consumption were found [168]. In another study, the metabolic 
profiling approach using high resolution 
1
H-NMR spectroscopy has been applied to study metabolite 
changes in human feces by the intake of grape juice and ethanol-free wine extracts [169] (see Figure 
5). This study showed changes in the levels of isobutyrate when the mixture of juice and wine was 
taken but could not find any difference in the metabolic profile due to the intake of juice. This could 
be explained through the modulation of microbial gut metabolism produced by the polyphenols 
present in wine. Metabolic profiling after dietary intervention with soy isoflavones has also been 
determined by 
1
H-NMR differences in lipoprotein, amino acids and carbohydrate levels in plasma 
from five healthy pre-menopauseal women, thus suggesting a metabolic alteration due to soy 
consumption. [170]. In another 
1
H-NMR study on the effect of soy isoflavones, an improvement in 
renal function and an increase in the urinary excretion of the osmolyte trimethylamine-N oxide has 
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been proven [171]. A summary of main Metabolomic applications in Nutrigenomics field are listed in 
Table 3. 
 
Coupling of NMR with separation techniques is less extended than in MS, but can also give interesting 
results in Metabolomics. Offline coupling with solid-phase extraction (SPE) or on-line coupling with 
HPLC are the most extended in metabolomic research. For example HPLC-NMR has been used for 
the identification of hippuric acid, 3-(3-hydroxyphenyl) propionic acid, and 3-hydroxycinnamic acid 
in rat urine using reverse phase gradient HPLC coupled with 
1
H-NMR [172].  
 
The lack of sensitivity of NMR, in the range of μg, has been one of the main problems of this 
analytical technique. However, the recent introduction of new instrumentation, like 
1
H-detection triple 
resonance cold probes, or different approaches such as dynamic nuclear polarization, have provided an 
improvement in detection sensitivity that will increase even further the number of applications of 
NMR in metabolomic studies [173]. 
 
4.2. Data analysis in Metabolomics. 
 
Due to the huge amount of data obtained in metabolomic studies, it has been necessary to develop 
strategies to convert the complex raw data obtained into useful information. Metabolomic data 
reduction is normally accomplished using principal component analysis (PCA) or other related 
techniques. PCA is a tool for exploratory data analysis that determines correlation differences among 
sample sets, which can be caused by either a biological difference or a methodological bias. It is 
usually used as a first step to have information about the quality of the data. After data reduction a 
multivariate analysis is usually performed. The most common is partial least square discriminant 
analysis (PLS-DA). The aim of PLS-DA is to discriminate the complete peak list and reduce it with 
the most relevant ones [151].  
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Once an unknown compound is determined, the following challenge is to identify it and determine its 
biological significance [148]. For this matter, there are different large-scale databases available on the 
web. One of the most accessed databases available online is KEGG [174]. In particular for Nutritional 
Metabolomics the most interesting biochemical databases are the ones operated by the European 
Nutrigenomics Organization [175] that allows to upload and edit scientific information, and the 
Human Metabolome Database [176, 177], which provides information on more then 2180 metabolites 
from human. For all these reasons, Metabolomics has been considered in the NIH roadmap as an 
interesting tool for the overall initiative to carry out possible solutions to human metabolic diseases 
[88]. 
 
5. Systems Biology. 
 
Nutrigenomics has to face important difficulties derived, among others, from food complexity, the 
large number of different nutrients and bioactive food compounds, their very different concentrations 
and the numerous targets with different affinities and specificities that they may have. As described 
above, Transcriptomics, Proteomics and Metabolomics represents powerful analytical platforms 
developed for the analysis of genes, proteins and metabolites. However, „omics‟ platforms need to be 
integrated in order to obtain optimal means to understand the influences of bioactive food components 
on the investigated system (e.g., cell, tissue, organ) giving rise to the growing of a new  area of 
biology called Systems Biology.  Modern Systems Biology is the analysis of the relationships among 
the elements in a system in response to genetic or environmental perturbations, with the goal of 
understanding the system or the emergent properties on the system [178-180]. Thus, Systems Biology 
approaches may encompass molecules, cells, organs, individuals, or even ecosystems and it is 
regarded as an integrative approach of all information at the different levels of genomic expression 
(mRNA, protein, metabolite). However, in Nutrigenomic studies biologic responses to a bioactive 
food component may be subtle and, therefore, careful attention will need to be given to the 
methodologies used to identify these responses. Unlike any reductionist approach that would take 
these techniques individually, Systems Biology exploits global data sets to derive useful information 
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[181]. Each large data set contains sufficient noise to preclude the identification of multiple minor but 
relevant changes that could be unnoticed without adequate statistical tools since the researcher is 
focused on the changes that are really significant within the whole data set. Systems Biology, 
however, by confining the information can provide a filter for “distracting” noise generated in each 
individual platform and minimize the data to be interpreted by focusing on only those endpoints 
common between the various experimental platforms [178, 182]. To achieve this, appropriate 
statistical models have to be used in order to filter through the large data sets and highlight only those 
important changes. Although Systems Biology has been scarcely applied in Nutrigenomic studies, 
their potential is underlined by their adoption by other disciplines. For instance, a Systems Biology 
approach has been applied to improve our knowledge about carbohydrate metabolism in yeast [178]. 
In a recent work, Kohanski et al. used the context likelihood of relatedness (CLR) algorithm (gene 
network analysis) in combination with gene expression microarrays and Gene Ontology-based 
enrichment analysis to construct and filter gene connectivity maps of bacteria under antibiotic 
treatment [183]. The gene networks were further enriched with data derived from antibiotic growth 
high-throughput screening to provide insight into the pathway whereby the antibiotic under study 
triggers its bactericide action.  
 
An adequate Systems Biology approach in Nutrigenomics should provide a holistic view of the 
molecular mechanisms underlying the beneficial or adverse effects of certain bioactive food 
components. Also, it should help in the discovery of key genes and proteins that function to regulate 
metabolic pathways and whose expression is affected by specific bioactive food compounds. This will 
aid in rapidly identifying new biomarkers for nutritional status and disease progression, and designing 
a novel concept for dietary prevention and intervention of disease [16]. 
 
6. Future needs and developments in Nutrigenomics. 
 
Despite the use of DNA microarrays is a powerful analytical approach, there are technical limitations 
that have to be addressed for optimal implementation. Some of these problems are associated with the 
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high background noise that specially hinders the detection of low signals (i.e., low signal-to-noise 
ratios). Novel approaches focused on the use of electrochemical transducers in combination with either 
enzymatic, redox-active indicators, or nanoparticle labels, as well as with label-free hybridization 
strategies are being investigated as cheaper and sensitive alternatives to current optical detection 
systems [184, 185]. A second problem is related to the efficiency and specificity of the hybridization 
reaction that is subject to variability and cross-hybridization and thus, it affects the ability of the 
technique to accurately detect differences in gene expression levels [41]. In this regard, some 
interesting alternatives to typical linear probes have been proposed such as molecular beacon probes 
and peptide nucleic acids [185]. These probes offer high specificity and appear as good candidates for 
mismatch discrimination. Still, problems derived from element-to-element differences within a 
microarray and microarray-to-microarray differences need also to be solved [23, 186]. For that, the 
MicroArray Quality Control (MAQC) Consortium establishes quality control criteria to ensure data 
quality, to identify critical factors affecting data quality, and to optimize and standardize microarray 
procedures [187]. 
 
Although microarrays is currently the technique of choice for profiling RNA populations under 
different conditions, some advantages of RNA-Seq over existing technologies make this technique 
valuable for comprehensive transcriptome studies. First, unlike hybridization-based approaches, which 
rely on continuous signals, RNA-Seq consists of absolute numbers of reads that provide accurate 
estimates of the relative abundance of given transcripts and it is exempt from cross-hybridization 
problems [72, 188]. In addition, dynamic range of expression level in RNA-Seq depends of the 
sequencing depth total number of all the sequences reads or base pairs represented in the experiment) 
and it has been reported to be larger (up to five orders of magnitude) than the one provided by 
microarray scanners (few-hundredfold) [189]. Contrary to microarray, RNA-Seq has very low 
background signal because DNA sequences can be unambiguously mapped to unique regions of the 
genome, allowing detection of very low expressed mRNA, provided that sequencing depth is 
sufficient [190]. Another important advantage of RNA-Seq relative to gene expression microarray is 
their ability to identify, without prior knowledge, spliced transcript isoforms [191] and sequence 
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variations such as single nucleotide polymorphisms (SNPs) in the transcribed regions [66]. Despite of 
these advantages, RNA-Seq currently faces several challenges including those concerning library 
construction issues, bioinformatics and complete coverage at reasonable costs. RNA-Seq does not 
require cloning, however, the library construction involves some manipulation stages and procedures 
that could originate some bias [66]. Also, one of the main limitations of RNA-Seq stems from the 
short length of the sequence reads provided. For large and complex transcriptomes, mapping the short 
reads to the reference transcriptome can be complicated, especially if an important fraction of 
sequence reads match multiple locations in the genome. In such case, longer reads and paired-end read 
sequencing, based on sequencing both ends of each interrogated DNA fragment, have been proposed 
to help to alleviate the problem [72]. Sequencing depth is another important aspect that affects 
sequence coverage (percentage of transcripts surveyed), determines the number of expressed genes 
and rare spliced isoforms detected and is directly proportional to the sequencing costs [192].  
 
Next-generation methods in Transcriptomics will undoubtedly continue to technically improve in 
several ways within the next years. New improvements will probably include the establishment of 
routine data analysis methods and increases in the numbers and lengths of sequence reads as well 
[193, 194]. Fortunately, the cost is likely to keep falling, allowing next-generation sequencing 
methods demonstrate full potential for the study of transcriptomes and provide new applications and 
extensive use of these technologies in Nutrigenomics research. 
 
In Proteomics, 2DE, LC, CE and MS have become the most used methodologies. There is an evident 
need of development of improved or alternative technologies to become into a reality the routine 
analysis for proteome research. In this sense it has been proved the robustness of MudPIT for the 
analysis of complex mixtures of peptides; however improvements in the resolution of peptides are 
desirable to provide increased protein coverage. On the other hand, although much less employed than 
the methodologies used today in Proteomics, it is expected that relatively new protein microarray 
technology will play an important role in Proteomics in the near future due to the possibility to  
simultaneously analyze a large number of different proteins, providing unique opportunities to 
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establish interrelationship between dietary components and the development and/or progression of 
diseases. Apart of the everyday more sophisticated sample treatments and separation techniques, MS 
is essential for the systematic investigation in Proteomics. Rapid advances in MS instrumentation, 
both in terms of hardware and software, are improving current technologies and have catalyzed the 
development of new proteomic approaches. In this sense, conventional mass spectrometers are giving 
way to the more sophisticated and compact mass spectrometers, most of them hybrid instruments in a 
combination of two or more analyzers. As can be seen in the low number of proteomic applications in 
Nutrigenomic studies, it is expected that new innovations in proteomic technology will help proteomic 
profiling to become standard practice in the Nutrigenomic field. 
 
In addition, a great advance in Metabolomics is expected related to the Nutrigenomics field with the 
incorporation of new interfaces such as desorption electrospray ionization (DESI) [195], SELDI [196], 
nanostructure-initiator mass spectrometry (NIMS) or with system miniaturization (nanoESI) [197]. 
These interfaces have the advantage that they need nearly no sample preparation. On the other hand, 
capillary electrokinetic techniques and their coupling to mass spectrometry (CE and CE-MS) are ideal 
tools for Metabolomics, due to the wide variety of applications, great efficiency and resolution, and 
low sample consumption. Although CE and CE-MS have not been widely used, they have already 
been identified as a very promising tool for metabolomic studies [161, 198, 199]. Thus, CE has been 
recently used to evaluate the response to vitamin E and D of diabetic rats metabolite urine profile with 
two different CE approaches (one based in micellar electrokinetic capillary chromatography (MEKC) 
and another using capillary zone electrophoresis (CZE)). With these new analytical methods it could 
be proved that the metabolic profile of diabetic rats fed with a mixture of these antioxidants trend to be 
similar to that from non diabetic control rats [200]. 
 
Comprehensive multidimensional techniques, such as GCxGC or LCxLC, are also a revolutionary 
improvement in separation techniques that will be implemented in Nutritional Metabolomics studies in 
the near future. They not only provide enhanced resolution and a huge increase in the peak number but 
also an increase in selectivity and sensitivity in comparison with conventional separation techniques. 
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As an example, comprehensive GCxGC coupled to TOF-MS has demonstrated to be a promising tool 
for metabolic profiling [201], and it has been successfully used for the detection of biomarkers in 
obese mouse tissue [202].  
 
The challenge in Systems Biology approach is not on the technological level, as great improvements, 
as discussed here, are being made in the „omics‟ technologies. Instead, it will be the bioinformatics 
side (data processing, clustering, dynamics, integration of the various „omics‟ levels, etc.) that will 
have to progress for systems biology to mature and expand into Nutrigenomics.  
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FIGURE LEGENDS 
 
Figure 1. Scanned image of a microarray composed of a total of 250 kinases and phosphatases 
showing the expression profile obtained from human prostate carcinoma LNCaP cells treated with 12 
mM epigallocatechin gallate (EGCG) or water-only for 12 h. Redrawn from [53].  
 
Figure 2. Workflow of multidimensional separation-MS/MS-based shotgun proteomics strategy. N is 
the sample fraction. Redrawn from [126]. 
 
Figure 3. SELDI–TOF mass spectra representing protein expression differences in plasma of vitamin 
A-deficient (n=3) and vitamin A-sufficient (n=3) rats at three different m/z: 10693, 15203 and 18720. 
Bold line, vitamin A-sufficient Mr profile; dotted line, vitamin A-deficient Mr profile. Redrawn from 
[143]. 
 
Figure 4. Metabolomics workflow in Nutrigenomics research. 
 
Figure 5. NMR profiles of faeces from different subjects using two different extraction methods 
(water and methanol). Redrawn from [169].  
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Figure 2 
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Figure 3 
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Figure 4 
1. Samples (urine, blood...) 
2. Metabolite extraction 
3. Separation (GC, LC, CE, GCxGC...) 
4. Detection and characterization (MS, NMR) 
5. Statistical Analysis (PCA, PLS-DA) 
6. Elucidation (KEGG, HMDB, NuGO...) 
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Figure 5 
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Table 1. Applications of expression DNA microarrays in Nutrigenomics research. 
 
 
Bioactive 
compound/ Food 
ingredient 
Food/ 
beverage 
Studied model 
Expected effect/target 
illness 
Analytical 
methodology 
Ref. 
Anthocyanins C3G 
and cyanidin Cy 
Fruits, 
vegetables, 
red wine 
Human adipocyte 
cells 
Regulation of adipocyte 
function 
Affymetrix Human 
Genome  microarray  
[37] 
Astaxanthin Fish, algae Mice Regulation of oxidative 
phosphorylation and 
oxidative stress 
Affymetrix Mouse 
Expression 
microarray  
[52] 
Chlorella algae  
intake 
Diet Healthy men 
(blood cells) 
Regulation of fat and 
glucose metabolism. 
Modulation of glucose 
sensitivity in humans 
Custom diabetes-
related microarray 
(Hitachi) 
[6] 
Epicatechin Cocoa Human colon 
adenocarcinoma 
Caco-2 cells 
Prevention of the 
oxidative DNA 
damage, reduction of 
inflammatory response 
Clontech Human 
Haematology 
microarray  
[36] 
Epigallocatechin-3 
gallate 
Green tea Human bronchial 
epithelial 21BES 
cells 
Chemopreventive agent 
in cancer 
Custom printed 
Human microarray  
[35] 
  Human prostate 
carcinoma LNCaP 
cells 
Anti-proliferative 
action 
cDNA 
microarray  
[53] 
  Human HT 29 
colon carcinoma 
cells 
Anti-proliferative 
action 
Affymetrix Human 
Genome microarray  
[40] 
Genistein Soybean Postmenopausal 
women (peripheral 
lymphocytes) 
Regulation cAMP 
signalling and cell 
differentiation 
Human oligo 
microarrays  
[24] 
High-Cholesterol 
intake 
Diet Rats Effects in 
cardiovascular disease 
Custom printed 
cDNA microarray 
[54] 
High-protein / 
high-carbohydrate 
intakes 
Dairy-based 
breakfasts 
Healthy men 
(blood cells) 
Regulation of glycogen 
metabolism and protein 
biosynthesis 
Affymetrix Human 
Genome microarray 
[50] 
Long chain 
polyunsaturated 
fatty acids 
Fish oil Mice Regulation of hepatic 
beta-oxidation and 
gluconeogenesis 
Affymetrix Murine 
Genome microarray  
[48] 
Low-calorie intake Diet Obese men (blood 
cells) 
Regulation of oxidative 
stress and inflammation 
Agilent Human Oligo 
microarray 
[55] 
Omega-3 fatty acid Fish oil Human colon 
adenocarcinoma 
Caco-2 cells 
Chemopreventive agent 
in cancer 
Clontech Human 
Atlas Glass Arrays  
[49] 
Quercetin Fruits and 
vegetables 
CO115 colon-
adenocarcinoma 
cells 
Chemopreventive agent 
in cancer 
Affymetrix Human 
Genome microarray 
[56] 
Sulforaphane Cruciferous 
vegetables 
Mice Chemopreventive agent 
in cancer  
Affymetrix Murine 
Genome microarray 
[39] 
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Table 2. Applications of Proteomics in Nutrigenomics research. 
 
 
Bioactive 
compound/ 
Food ingredient 
Food/ 
beverage 
Studied model Expected effect/ 
target illness 
Analytical 
methodology 
Ref. 
Quercetin - Human SW480 
colon carcinoma 
cells 
Colorectal cancer 
prevention  
2DE, MALDI-TOF 
MS 
107 
Fatty acids Dietary 
fish oil 
Leiden 
transgenic mice  
Lipid and glucose 
metabolism study 
2DE, MALDI-TOF 
MS 
108 
Ginestein and 
daidzein 
isoflavones 
Soy extract Human 
endothelial cells 
Atherosclerosis-
preventive activities 
2DE, MALDI-TOF 
MS 
[109-
113] 
Isoflavones Cereal bars Human 
peripheral blood 
mononuclear 
cells 
Atherosclerosis-
preventive activities 
2DE, MALDI-TOF 
MS 
[113] 
Monacolin K Fungus Caco-2 cells Chemopreventive 
agent in cancer 
2DE, MALDI-
TOF/TOF MS 
[114] 
Volatile 
compounds 
Coffe bean Rat brain Antioxidart and stress 
relaxation 
2DE, MALDI-TOF 
MS, MALDI-Q-
TOF MS/MS 
[115] 
Polyphenols Green tea Human lung 
adenocarcinoma 
A549 cells 
Anticancer activity 2DE, nLC-ESI-Q-
TOF MS/MS 
[116] 
No specific 
bioactive 
compound 
Diets with 
different % 
of 
vegetable 
Mouse colon 
mucosal cells 
Colorectal cancer 
prevention 
2DE, MALDI-TOF 
MS 
[117] 
Isoflavones Soya foods Human serum Vascular protection DIGE, LC-MS/MS [118] 
Vitamin A - Rat plasma Changes in 
nutritional status 
SELDI-TOF [143] 
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Table 3. Metabolomics applications in Nutrigenomics research. 
 
 
Bioactive 
compound/ 
Food ingredient 
Food/ 
beverage 
Studied 
model 
Expected 
effect/target illness 
Analytical 
methodology 
Ref. 
Phytochemicals Low and 
standard 
phytochemical 
diet 
Human 
urine 
samples 
Acute effects in 
urinary metabolism 
1
H-NMR and 
HPLC-ESI-Q-
TOF  
[159] 
Flavonoids/Phen
olic compounds 
Red wine/Red 
grape juice/ 
Tea 
Human 
urine, 
plasma and 
fecal 
samples.. 
Reduce risk of 
cardiovascular disease 
via study of the gut 
microbial impact in 
polyphenols 
GC-TOF-MS [164] 
Polyphenols Chamomile tea Human 
urine 
samples 
Increased excretion of 
hippurate and glycine 
and depleted of 
creatinine 
1
H-NMR [168] 
Polyphenols Wine/Grape 
Juice 
Human fecal 
samples 
Modulation of the gut 
microflora to prevent 
inflammatory bowel 
1
H-NMR [169] 
Isoflavones Soy enriched 
diets 
Human 
plasma 
samples 
Changes in 
carbohydrate and 
energy metabolism. 
1
H-NMR
 
[170] 
Isoflavones Soy enriched 
diets 
Human 
urine 
samples 
Improved glomerular 
function or general 
kidney function 
1
H-NMR [171] 
 
 
